[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Children's Hospital Medical Center, Cincinnati\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":586},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,119,0,25,[9,42,66,90,114,140,170,191,202,225,247,267,284,304,321,337,375,396,417,442,463,505,525,548,560],{"id":10,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":22,"keywords":24,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":41},"100054258",false,"NCT07666048","Adapting Enhanced Supports to Improve Patient Adherence to Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease","SHIELD 3 Adapt","Inclusion Criteria:\n\n* Adults living with rheumatic heart disease (RHD): age ≥18 years; diagnosed with RHD; prescribed secondary antibiotic prophylaxis (SAP)\n* Guardians of children living with RHD: age ≥18 years; caregiver\u002Fguardian of a child aged 5-17 years with diagnosed RHD who is prescribed SAP\n* Children living with RHD: age 12-17 years; diagnosed with RHD; prescribed SAP\n* Community health workers (CHWs): age ≥18 years; associated with a healthcare center providing care to patients with RHD\n* Healthcare workers (HCWs): age ≥18 years; employed at a healthcare center providing care to patients with RHD; able to provide informed consent in English or the local language\n\nExclusion Criteria:\n\n* Adults living with RHD: medical contraindication to SAP; inability to provide informed consent (e.g., significant cognitive or communication impairment precluding participation)\n* Guardians of children living with RHD: child has a medical contraindication to SAP; inability to provide informed consent\n* Children living with RHD: medical contraindication to SAP; inability to provide informed assent (e.g., significant cognitive or communication impairment precluding participation)\n* Community health workers: none\n* Healthcare workers: none","ALL",{"count":18,"type":19},308,"ESTIMATED","OBSERVATIONAL","The goal of this clinical trial is to test the effectiveness and implementation of enhanced Secondary Antibiotic Prophylaxis (SAP) supports using a hybrid type 1 effectiveness-implementation design. The purpose is to determine whether enhanced SAP supports will increase average SAP adherence in Brazil and Timor-Leste. The study will enroll people living with Rheumatic Heart Disease (RHD) and Community Health Workers (CHWs) participating in the intervention.\n\nThe main questions it aims to answer are:\n\n* Whether CHW-led supports delivered within the community improve mean SAP adherence at 12 months post-intervention.\n* Whether the intervention demonstrates acceptability, feasibility, uptake and engagement.\n\nResearchers will compare baseline and post-intervention SAP adherence data for the 12 months prior to and following intervention rollout to see if CHW-delivered supports increase adherence.",[23],"Rheumatic Heart Disease in Children",[25,26,27,28],"Secondary Antibiotic Prophylaxis for Rheumatic Heart Disease","SAP for RHD","SAP Adherence","Secondary Antibiotic Prophylaxis Adherence","NOT_YET_RECRUITING","2026-07-10",{"date":32,"type":33},"2026-07-13","ACTUAL",{"date":35,"type":19},"2026-08-01",{"date":37,"type":19},"2030-12-31",{"name":39,"class":40},"Children's Hospital Medical Center, Cincinnati","OTHER",1,{"id":43,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":50,"targetDuration":4,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":58,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":63,"leadSponsor":65,"locationsCount":41},"100053888","NCT07606131","Testing a Registry-Based Strategy (ACT+) to Reduce Loss to Follow-Up in Rheumatic Heart Disease Screening in Uganda","Developing and Testing a Registry-Enabled Strategy (ACT+) to Reduce Loss to Follow-Up Between Screening and Confirmation of Rheumatic Heart Disease in Uganda","SHIELD 2","Inclusion Criteria: Community Members\n\n* 18 years of age or older\n* Received a positive ADUNU echocardiographic screening result within the past 24 months OR parent\u002Flegal guardian of a minor who received a positive ADUNU echocardiographic screening result within the past 24 months\n\nInclusion Criteria: Providers\n\n* Employed at an ADUNU-participating facility or confirmatory echo facilities at the time of study\n* Holds a designated ADUNU role (nurse screener, confirmatory provider, or referral support staff) or is involved in RHD screening, diagnosis or care\n* Ability to provide informed consent in Acholi, Luo, or English\n\nInclusion Criteria: Regional RHT ACT Nurse Coordinator\n\n* Employed as a Regional ACT Nurse at the time of study\n* Has familiarity with ADUNU program\n* Ability to provide informed consent in Acholi, Luo, or English\n\nInclusion Criteria: District Health Office Team Members and District RHD Focal Persons\n\n* Employed at District Health Office within an ADUNU-participating district\n* Has familiarity with ADUNU program\n* Ability to provide informed consent in Acholi, Luo, or English\n\nExclusion Criteria:\n\n* No formal exclusion criteria beyond inability to provide informed consent. Individuals with significant cognitive or communication impairment precluding interview participation will not be enrolled.",true,{"count":51,"type":19},16,"INTERVENTIONAL",[54],"NA","This study aims to improve follow-up care after positive rheumatic heart disease (RHD) screening in Northern Uganda. It will identify barriers and co-develop an enhanced ACT+ strategy, then evaluate its effectiveness in increasing linkage to confirmatory echocardiography, along with its adoption, acceptability, and feasibility. Secondary outcomes include time to diagnosis, initiation of treatment, and factors influencing implementation.",[57],"Rheumatic Heart Disease",[59,60],"Rheumatic heart disease","SHIELD",{"date":32,"type":33},{"date":35,"type":19},{"date":64,"type":19},"2028-06-01",{"name":39,"class":40},{"id":67,"slug":4,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":72,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":52,"phases":75,"briefSummary":76,"conditions":77,"keywords":80,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":41},"100528312","NCT06159127","SMART@Home Feasibility Trial","Self-Management Assistance for Recommended Treatment (SMART)@Home Care","Inclusion Criteria:\n\n* Patients diagnosed with a chronic medical condition requiring regular treatment, i.e., asthma\n* Ages 12-18\n* English fluency for patient and caregiver\n\nExclusion Criteria:\n\n* Diagnosis of pervasive developmental disorder in patient or caregiver as determined by medical chart review\n* Diagnosis of serious mental illness (e.g., schizophrenia) in patient or caregiver as determined by medical chart review","12 Years","18 Years",{"count":7,"type":19},[54],"The proposed research addresses the limitations or lack of a digital platform to provide remote care of medically complex patients. Previous attempts have had poor clinical validity and suffered lack of patient engagement. The study team will deconstruct the previously implemented SMART platforms to create a roadmap, platform, and template to guide clinicians to create new tools.\n\nResults from Phase 1 of this project highlighted the need for connectivity between the SMART@Home app and Bluetooth-enable devices to provide objective disease activity data as well as integration with Epic electronic health record so that providers can use the data to inform treatment planning and decision making. A subsequent pilot user validation trial is also needed to confirm development goals were met. Conducting a pilot user validation trial of the SMART@Home asthma tracker, spirometer, and action plan is the purpose of the next phases of this study.\n\nA beta test the SMART@Home Asthma Tracker and asthma action plan algorithm will take place with approximately 8 participants. Beta testing will have participants record simulated increases in symptoms to ensure appropriate levels of care is communicated via the app. Then, a group of 40 adolescent (ages 12-17) patients with asthma for a 6-month pilot Randomized Control Trial (RCT). Participants will be randomized into either the IMAAP SMART@Home (n=20) or control (n=20) groups following the completion of baseline measures to test the interactive asthma action plan functionality and impact.",[78,79],"Asthma","Asthma in Children",[78],"RECRUITING","2026-06-30",{"date":84,"type":33},"2026-07-02",{"date":86,"type":33},"2024-09-09",{"date":88,"type":19},"2027-07-31",{"name":39,"class":40},{"id":91,"slug":4,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":49,"sex":16,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":52,"phases":100,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":106,"lastUpdatePostDateStruct":107,"startDateStruct":109,"completionDateStruct":111,"leadSponsor":113,"locationsCount":41},"100570906","NCT06713330","Comparing Stainless Steel Crowns With Prefabricated Resin Crowns in Primary Molar Teeth","A 36-Month Prospective Randomized Clinical Pilot Trial Comparing Stainless Steel Crowns With Prefabricated Resin Crowns in Primary Molar Teeth","Inclusion Criteria:\n\n* CCHMC pediatric dental patients between the ages of 2 years to 5 years and 11 months, at the time of recruitment, who present to any CCHMC dental clinic location and then are found to need full mouth dental rehabilitation.\n* Patients who speak the most common languages at CCHMC will be able to be recruited for the study.\n\n  o English, Spanish, Arabic, Uzbek, Nepali, Chinese Mandarin, Russian, French.\n* These patients must qualify for treatment at the CCHMC dental in-office general anesthesia (IOGA) area or the Procedure Center (PC). IOGA and the PC will be selected as a venue of treatment to control behavioral factors. This is not specific to the study and would occur due to their treatment needs.\n* Participants will have at least one pair of contralateral primary molars with the need for a full coverage restoration in the same arch.\n\n  * For example, tooth A \\& J, B \\& I, S \\& L, or T \\& K\n  * For each participant, a minimum of one SSC or one PRC will be randomly assigned via a split mouth design to be placed as part of the study.\n* Need for Full coverage and high caries risk will be defined by AAPD Best Practice Guidelines 2,16\n\n  o Teeth With\n  1. Extensive caries\n  2. Cervical decalcification\n  3. Developmental defects (e.g., hypoplasia, hypocalcification)\n  4. When failure of other available restorative materials is likely (e.g., interproximal caries extending beyond line angles, patients with bruxism)\n  5. Following pulpotomy or pulpectomy\n  6. For definitive restorative treatment for high caries-risk children as defined by the AAPD\n  7. For patients who exhibit high caries risk and whose treatment is performed under sedation or general anesthesia. This would be normal and not specific to the study.\n* Participants who consent to the study, and who can be available for follow-up recall appointments.\n* All participants will be ASA I or ASA II as defined by the American Society of Anesthesiologists.15\n\nExclusion Criteria:\n\n* Participants who do not meet inclusion criteria will be excluded.\n\n  * Participants whose teeth do not meet the inclusion criteria.\n  * Participants who do not wish to participate in the study.\n  * Patients who do not wish to or cannot reliably return for follow-up visits.\n  * Red dye allergy as patient will not be able to be plaque disclosed during follow-up visits.\n  * Participants who do not speak English, Spanish, Arabic, Uzbek, Nepali, Chinese Mandarin, Russian, French.","2 Years","5 Years",{"count":99,"type":19},50,[54],"The main reason for this research study is to learn more about a new flexible white dental crown (BioFLX) by comparing it to an existing flexible metal crown (Stainless Steel Crown). It is of interest to see if this new white crown is clinically equivalent to the existing silver crown that is mainly used in pediatric dentistry. A potential participant for this study would have cavities that require a crown, a type of filling that covers the entire tooth, and recommended dental work be done under general anesthesia.",[103],"Dental Caries",[105],"Pediatric dentistry","2026-06-24",{"date":108,"type":33},"2026-06-29",{"date":110,"type":33},"2024-05-17",{"date":112,"type":19},"2027-12-29",{"name":39,"class":40},{"id":115,"slug":4,"hasResults":11,"nctId":116,"briefTitle":117,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":11,"sex":16,"minAge":119,"maxAge":120,"enrollmentInfo":121,"targetDuration":4,"studyType":52,"phases":123,"briefSummary":124,"conditions":125,"keywords":128,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":139},"100610121","NCT07223463","A Tailored Medication Adherence-Promotion Intervention for Adolescents and Young Adults With Cancer","Inclusion Criteria:\n\n* Patient is 15.00 to 24.99 years of age\n* Patient is diagnosed with cancer\n* Patient is prescribed an oral anticancer\u002Fantitumor agent or prophylaxis\n\nExclusion Criteria:\n\n* Patient is not fluent in English\n* Patient evidences significant cognitive deficits\n* Patient's medical status or treatment precludes participation\n* Patient enrolled on a medical trial requiring medication storage in a trial-provided container\n* Patient demonstrates greater than or equal to 95% adherence during run-in period\n* Patient declines to use or has difficulty using electronic adherence monitoring device during run-in","15 Years","24 Years",{"count":122,"type":19},160,[54],"The goal of this clinical trial is to learn if a tailored intervention can help make it easier for adolescents and young adults with cancer to take their medications. The main questions the researchers are trying to answer are:\n\n* Does the tailored intervention increase adherence?\n* Does the tailored intervention improve quality of life?\n* Does the tailored intervention reduce health care utilization?\n\nThe researchers will compare the tailored intervention to a uniform standard of care intervention (an intervention designed to be similar to what is currently happening in clinical care) to see if the tailored intervention works to improve adherence.\n\nParticipants will:\n\n* Use an electronic pill bottle or box to store their medication\n* Participate in intervention sessions\n* Complete surveys before the intervention, after the intervention, and 6-months later",[126,127],"Cancer","Medication Adherence",[129,130,131],"adolescents and young adults","cancer","adherence","2026-06-23",{"date":106,"type":33},{"date":135,"type":19},"2026-09-01",{"date":137,"type":19},"2030-08-31",{"name":39,"class":40},4,{"id":141,"slug":4,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":147,"enrollmentInfo":148,"targetDuration":4,"studyType":52,"phases":150,"briefSummary":151,"conditions":152,"keywords":155,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":162,"startDateStruct":164,"completionDateStruct":166,"leadSponsor":168,"locationsCount":169},"100562884","NCT06608966","Epilepsy Journey-An Executive Functioning Intervention for Teens With Epilepsy","Epilepsy Journey 2.0: An Intervention to Improve Executive Functioning in Adolescents With Epilepsy","Inclusion Criteria:\n\n1. Age between 13-17 years at the time of enrollment\n2. Child lives at home with primary caregiver and is enrolled in school (excluding summer breaks).\n3. Confirmed diagnosis of epilepsy with seizures that are categorized as either generalized or focal in onset. Epilepsy is defined as: 1) At least two unprovoked seizures occurring more than 24-hours apart; or 2) One unprovoked seizure and a probability of further seizures similar to the general recurrence risk after two unprovoked seizures.\n4. Primary language of English\n5. Screening Inclusion: On the parent-reported Behavior Rating Inventory of Executive Function-2nd edition (BRIEF-2), have executive functioning deficits defined as at least 2 subclinical (60\\\u003CT\\\u003C65) or one clinical BRIEF-2 subscale T scores (T≥65).\n6. Parent\u002Flegal guardian(s) willing to sign an IRB approved informed consent\n7. Participant willing to sign an Institutional Review Board approved assent\n\nExclusion Criteria:\n\n1. Parent or clinician-reported history in the adolescent of:\n\n   1. developmental delay (e.g., autism spectrum disorder, pervasive development disorder, history of services for developmental delay or intellectual impairment in the past 5 years, known IQ\\\u003C70)\n   2. severe mental illness (e.g., schizophrenia, bipolar disorder, eating disorder within the past 12 months, depression with active suicidal ideation or suicidal ideation\u002Fintent in the past 3 months)\n   3. prior (3-months) or current history of trauma and\u002For stressor-related disorders (e.g. PTSD)\n   4. recent or current significant medical disease (i.e., cardiovascular, hepatic, renal, gynecologic, musculoskeletal, metabolic or endocrine)\n   5. brain injury or brain tumor; and\u002For\n   6. epilepsy surgery\n   7. any other medical and\u002For psychological condition that takes treatment precedence over the study intervention\n2. Clinician-reported diagnosis in the adolescent of\n\n   1. epilepsy whose seizures are categorized only as either unknown onset or unclassified onset (defined as insufficient information to determine onset)\n   2. epilepsy currently being treated at the time of enrollment by 3 or more antiseizure medications (ASMs) (excluding rescue medication use)\n   3. epilepsy with a history of failure to achieve seizure freedom despite adequate use of 4 different anti-seizure medications\n   4. a confirmed or suspected epileptic encephalopathy (e.g., electrical status epilepticus in sleep, Landau Kleffner syndrome, West syndrome)\n   5. a confirmed or suspected progressive and degenerative disorder (e.g., mitochondrial disorders, metabolic disorders, autoimmune disorders)\n   6. one or more episodes of status epilepticus within the 24 weeks prior to enrollment; and\u002For\n   7. treatable causes of seizures, for example identified etiologies including metabolic, neoplastic, or active infectious origin.\n   8. non-epileptic event\u002Fseizures\n3. Adolescents currently on the ketogenic diet\n4. Participation in a trial of an investigational drug or device within 30 days prior to screening","13 Years","17 Years",{"count":149,"type":19},310,[54],"The goal of this multi-site clinical trial is to determine the effectiveness of two components of a web-based intervention (Epilepsy Journey) to improve executive functioning in adolescents with epilepsy. The two components include web-based modules and problem-solving telehealth sessions with a therapist focused on executive functioning. This trial aims to answer the following questions:\n\n1. Which components of Epilepsy Journey (web-based modules or telehealth sessions with a therapist) are essential for improving executive functioning in adolescents with epilepsy?\n2. Which components of Epilepsy Journey (web-based modules or telehealth sessions with a therapist) are essential for improving quality of life in adolescents with epilepsy?\n\nParticipants will be randomly assigned to one of four groups: 1) Epilepsy Journey web-based modules and telehealth sessions, 2) Epilepsy Journey web-based modules only, 3) telehealth sessions with a therapist only, or 4) treatment as usual.\n\nParticipants will:\n\n* Independently review Epilepsy Journey web-based modules focused on executive functioning skills (\\~15-30 minutes) and\u002For have weekly telehealth sessions (\\~30-45 minutes) with a therapist for 14 weeks.\n* Complete measures of executive functioning (parent and teen-report) and quality of life (teen-report) at the start of the study, 14-, 26-, and 66- weeks after randomization. The NIH toolbox will be completed at the start of the study and 26-weeks after randomization. Additional measures will also be collected.",[153,154],"Epilepsy in Children","Executive Dysfunction",[156,157,158,159,160,161],"adolescents","executive functioning","seizures","epilepsy","behavioral trial","web-based intervention",{"date":163,"type":33},"2026-06-25",{"date":165,"type":33},"2024-11-11",{"date":167,"type":19},"2029-01-31",{"name":39,"class":40},3,{"id":171,"slug":4,"hasResults":11,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":175,"eligibilityCriteria":176,"healthyVolunteers":11,"sex":16,"minAge":177,"maxAge":178,"enrollmentInfo":179,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":181,"conditions":182,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":184,"lastUpdatePostDateStruct":185,"startDateStruct":186,"completionDateStruct":188,"leadSponsor":190,"locationsCount":41},"100462134","NCT05297708","Office, Home, and Ambulatory Blood Pressure","Office, Home, and Ambulatory Blood Pressure Measurements in Pediatric Patients","HBPA","Inclusion Criteria:\n\n1. Age 6 years to \\\u003C19 years old;\n2. Elevated blood pressure defined as 15% lower than the 95%ile BP based on clinical practice guidelines(CPG) but less than stage II hypertension based on CPG;\n3. Tolerate ABPM 24 hours;\n4. Tolerate HBP; and\n5. Can have diabetes mellitus, obstructive sleep apnea, and attention deficit hyperactivity disorder managed by medication.\n6. On stable doses of medications known to affect BP such as:\n\n   1. Corticosteroids\n   2. Calcineurin inhibitors\n   3. Oral decongestants;\n7. Clinically stable\n\nExclusion Criteria:\n\n1. On antihypertension medications or treated in the last 6 months;\n2. Pregnant;\n3. Structural heart disease such as:\n\n   1. Obstructive valvular disease\n   2. Coarctation of the aorta\n   3. Cardiomyopathy;\n4. Other secondary causes such as:\n\n   1. Renal artery stenosis\n   2. Neurological condition with dysautonomia;\n5. Recent initiation of medications known to affect BP such as:\n\n   1. Corticosteroids\n   2. Calcineurin inhibitors\n   3. Oral decongestants;","6 Years","19 Years",{"count":180,"type":19},52,"This will be a prospective observational study. The population would be pediatric patients 6 years to \\\u003C19 years of age who were referred for elevated blood pressure to investigate if home blood pressure (HBP) can determine blood pressure phenotype (normotensive, hypertensive, masked hypertension, white coat hypertension) as accurately as ambulatory blood pressure monitor (ABPM) in childhood and adolescence.",[183],"Elevated Blood Pressure","2026-06-22",{"date":163,"type":33},{"date":187,"type":33},"2022-03-24",{"date":189,"type":19},"2028-01-01",{"name":39,"class":40},{"id":192,"slug":4,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":21,"conditions":194,"keywords":195,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":201,"locationsCount":41},"100644246",{"count":18,"type":19},[23],[25,26,27,28],"2026-06-18",{"date":106,"type":33},{"date":199,"type":19},"2026-06-01",{"date":37,"type":19},{"name":39,"class":40},{"id":203,"slug":4,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":97,"maxAge":208,"enrollmentInfo":209,"targetDuration":4,"studyType":52,"phases":211,"briefSummary":213,"conditions":214,"keywords":215,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":219,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":41},"100604171","NCT07146048","A Non-Inferiority Trial of Stopping Penicillin in Early Rheumatic Heart Disease: GOAL-Stop","GOAL-Stop","Inclusion Criteria:\n\n* Participated in GOALIE\n* Concluded GOALIE with either echocardiographic normalization or stable mild RHD\n* Between ages 5-20 years at time of enrollment\n\nExclusion Criteria:\n\n* RHD Stage C\u002FD at GOALIE end of study echocardiogram\n* Relocation to extremely distant residence or school\n* Clinically documented penicillin allergy","20 Years",{"count":210,"type":19},922,[212],"PHASE3","GOAL-Stop is a randomized, controlled, non-inferiority trial designed to evaluate whether discontinuing secondary antibiotic prophylaxis (SAP) is non-inferior to continuing SAP in preventing progression of rheumatic heart disease (RHD) among children and adolescents. The trial will enroll participants aged 5-20 years with previously diagnosed mild RHD who have received at least 2 years of SAP and who demonstrate either echocardiographic normalization or stability (persistent mild RHD). Participants will be randomized to either continue SAP or discontinue SAP for 2 years. The primary outcome is echocardiographic progression of RHD at 2 years, assessed by blinded adjudicators using the 2023 World Heart Federation criteria. Subgroup analyses will evaluate outcomes in participants with echocardiographic normalization versus stable mild RHD, and an exploratory analysis will assess whether outcomes differ by prior prophylaxis route (oral vs. intramuscular).",[57],[59,216,217,218],"global health","secondary prophylaxis","children",{"date":184,"type":33},{"date":221,"type":33},"2026-03-23",{"date":223,"type":19},"2029-12-31",{"name":39,"class":40},{"id":226,"slug":4,"hasResults":11,"nctId":227,"briefTitle":228,"officialTitle":228,"acronym":4,"eligibilityCriteria":229,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":120,"enrollmentInfo":230,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":232,"conditions":233,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":239,"lastUpdatePostDateStruct":240,"startDateStruct":241,"completionDateStruct":243,"leadSponsor":245,"locationsCount":246},"100370061","NCT04098445","TRANSPIRE: Lung Injury in a Longitudinal Cohort of Pediatric HSCT Patients","Inclusion Criteria:\n\n* Subjects ≤ 24 years of age undergoing allogeneic or autologous HSCT.\n\nExclusion Criteria:\n\n* Subjects over 24 years of age.",{"count":231,"type":19},2000,"Hematopoietic stem cell transplant (HSCT) is an effective but toxic therapy and pulmonary morbidity affects as many as 25% of children receiving transplant. Early pulmonary injury includes diffuse alveolar hemorrhage (DAH), thrombotic microangiopathy (TMA) interstitial pneumonitis (IPS) and infection, while later, bronchiolitis obliterans is a complication of chronic GVHD associated with severe morbidity and mortality. Improved diagnosis and treatment of pulmonary complications are urgently needed as survival after HSCT improves, and as HSCT is increasingly used for non-malignant disorders such as sickle cell disease. Currently, there are large and important gaps in the investigator's knowledge regarding incidence, etiology and optimal treatment of pulmonary complications. Moreover, young children unable to perform spirometry are often diagnosed late, and strategies for monitoring therapeutic response are limited.\n\nThis is a prospective multi-institutional cohort study in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation (alloHSCT). Assembly of a large prospective uniformly screened cohort of children receiving HSCT, together with collection of biological samples, will be an effective strategy to identify mechanisms of lung injury, test novel diagnostic strategies for earlier diagnosis, and novel treatments to reduce morbidity and mortality from lung injury after transplant.",[234,235,236,237,238],"Hematopoietic Stem Cell Transplant (HSCT)","Diffuse Alveolar Hemorrhage","Thrombotic Microangiopathies","Interstitial Pneumonitis","Bronchiolitis Obliterans","2026-06-17",{"date":184,"type":33},{"date":242,"type":33},"2021-09-08",{"date":244,"type":19},"2033-09",{"name":39,"class":40},9,{"id":248,"slug":4,"hasResults":11,"nctId":249,"briefTitle":250,"officialTitle":250,"acronym":251,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":253,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":255,"conditions":256,"keywords":259,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":261,"lastUpdatePostDateStruct":262,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":266,"locationsCount":41},"100369718","NCT04093986","Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation","HELPFUL","Inclusion Criteria:\n\n* Medical records or data available from previous clinical care prior to June 20, 2019 of pregnant females with SCD, including women who miscarried, had a still birth, or completed labor at any gestational stage, with any hydroxyurea exposure during either pregnancy and\u002For while breastfeeding.\n* Medical records or data available from previous clinical care prior to June 20, 2019 about pregnancy and breastfeeding outcomes, both for babies with hydroxyurea exposure and other babies by these same women.\n\nExclusion Criteria:\n\n* Unavailable medical records or lack of information about hydroxyurea exposure.",{"count":254,"type":19},200,"The purpose of this research study is to document and understand the effects of hydroxyurea exposure for women with SCD and their babies, during both gestation and lactation.",[257,258],"Sickle Cell Disease","Sickle Cell Anemia",[260],"Hydroxyurea","2026-06-16",{"date":196,"type":33},{"date":264,"type":33},"2019-12-22",{"date":37,"type":19},{"name":39,"class":40},{"id":268,"slug":4,"hasResults":11,"nctId":269,"briefTitle":270,"officialTitle":270,"acronym":4,"eligibilityCriteria":271,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":272,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":41},"100641598","NCT07649213","Congenital Hemolytic and Dyserythropoietic Anemias","Inclusion Criteria:\n\n1. Patients who have been diagnosed, by medical history and review of the laboratory data obtained for clinical care, including CBC\u002Freticulocyte count and review of the blood smear, with a hereditary hemolytic anemia, where the genetic etiology is challenging to be identified.\n2. Parents and\u002For grandparents of children that have the above diagnosis. The parents and\u002For grandparents may or may not have non-immune hemolytic anemia (these will serve as positive or negative inherent controls)\n\nExclusion:\n\n1\\) Patients with anemias known to be acquired and not associated with a genetic etiology.",{"count":273,"type":19},400,"The main reason for this research study is to further understand how some red blood cells are formed incorrectly or they have an abnormal metabolism in a way that they break easier in the circulation or during their passage through the spleen.\n\nParticipants and\u002For family members diagnosed with non-immune hemolytic anemia due to a genetic disorder, such as, hemoglobin disorder, erythrocyte membrane skeleton disorders (e.g. spherocytosis, elliptocytosis, or stomatocytosis) or hydration defect (e.g. xerocytosis, overhydrocytosis) or red blood cell (RBC) enzyme disorders, or with a congenital dyserythropoietic anemia (CDA) will be asked to participate.",[276],"Hemolytic Anemia","2026-06-15",{"date":239,"type":33},{"date":280,"type":33},"2011-07-25",{"date":282,"type":19},"2052-07",{"name":39,"class":40},{"id":285,"slug":4,"hasResults":11,"nctId":286,"briefTitle":287,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":49,"sex":16,"minAge":177,"maxAge":289,"enrollmentInfo":290,"targetDuration":4,"studyType":52,"phases":292,"briefSummary":293,"conditions":294,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":299,"startDateStruct":300,"completionDateStruct":302,"leadSponsor":303,"locationsCount":41},"100617942","NCT07325175","Quantifying Motor Network Dynamics to Predict and Enhance Outcomes in Pediatric Dystonia","Inclusion Criteria:\n\n* For dystonia subjects:\n* Dx of dystonia (with and without DBS)\n* willingness and ability to complete study protocols.\n* For Typically Developing Controls:\n* normal developmental milestones\n* absence of any neuropsychiatric disorder\n* no significant medical condition.\n\nExclusion Criteria:\n\n* history of epilepsy\n* presence of implanted medical devices (except DBS in dystonia subjects)\n* lack of cognitive or physical ability to complete study protocol.","21 Years",{"count":291,"type":19},75,[54],"The goal of this study is to understand the development and progression of childhood dystonia, a movement disorder, in children. The main questions it aims to answer are:\n\nHow does the activity of the neural network evolve in children with dystonia in the context of motor development? What are the effects of chronic and active stimulation on cortical and subcortical motor network function in children with deep brain stimulation (DBS)?\n\nParticipants will:\n\n* Undergo noninvasive electrophysiological measurements (EEG, EMG) to quantify neural network activity. They will be tested at rest and during a simple motor reaction task.\n* Children with DBS will be assessed in the on and off DBS state to assess effects of chronic and active changes in motor network function.",[295,296,297,298],"Dystonia","Pediatric","Deep Brain Stimulation","Motor Development",{"date":261,"type":33},{"date":301,"type":33},"2024-01-01",{"date":223,"type":19},{"name":39,"class":40},{"id":305,"slug":4,"hasResults":11,"nctId":306,"briefTitle":307,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":310,"enrollmentInfo":311,"targetDuration":177,"studyType":20,"phases":4,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":315,"startDateStruct":316,"completionDateStruct":318,"leadSponsor":320,"locationsCount":139},"100539288","NCT06301893","Uganda Sickle Surveillance Study (US-3)","Prevalence and Mapping of Sickle Cell Trait and Disease in Uganda","Inclusion Criteria:\n\n* Up to 1,000,000 samples may be collected during 2015 - 2030 following primary analysis based on surveillance findings.\n\nExclusion Criteria:\n\n* Repeat samples on the same individuals during the study period will be excluded.","12 Months",{"count":312,"type":19},1000000,"It is estimated that over 250,000 babies are born with sickle cell disease (SCD) annually in sub-Saharan Africa, and only 10% - 50% of them survive beyond five years of age. Data describing the magnitude of the sickle cell problem are lacking in most African countries. The available data on prevalence were mainly from older studies and small numbers of hospitalized patients. In Uganda, approximately 25,000 children are born with SCD but 70-80% die before their 5th birthday. Lehmann and Raper found 'sicklaemia' prevalence of 0.8% and 45% in the Sebei and Bambaa ethnic groups, respectively. A recent study found a SCT and SCD prevalence of 3% - 19% and 0% - 3%, respectively but this study addressed only 5 of Uganda's 111 districts and used a small convenience sample of children aged 6 - 60 months. The objective of this study is to determine the prevalence and map out the burden of SCT and SCD in Uganda.",[257],{"date":261,"type":33},{"date":317,"type":33},"2013-09-07",{"date":319,"type":19},"2032-12-31",{"name":39,"class":40},{"id":322,"slug":4,"hasResults":11,"nctId":323,"briefTitle":324,"officialTitle":324,"acronym":4,"eligibilityCriteria":325,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":326,"targetDuration":119,"studyType":20,"phases":4,"briefSummary":328,"conditions":329,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":331,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":41},"100283048","NCT02964494","The Congenital Dyserythropoietic Anemia Registry (CDAR)","Inclusion Criteria:\n\n* Diagnosis of Congenital Dyserythropoietic Anemia (CDA), whether a genetic mutation is identified or not\n* Evidence of congenital anemia\u002Fjaundice or a positive family history\n* Evidence of ineffective erythropoiesis\n* Typical morphological appearance of bone marrow erythroblasts\n* All ages (ages 0-99)\n\nExclusion Criteria:\n\n* Diagnosis of cancer\n* Myelodysplasia\n* Secondary dyserythropoiesis: e.g.; vitamin B12 deficiency or drug-related.\n\nNote1: Patients with rare band 3 (SLC4A1) mutations recently described to be associated with dyserythropoiesis will be eligible since the mechanisms appear to involve direct participation of band 3 in the erythroblast mitosis and cytokinesis.\n\nNote2: Siblings, parents, and family members of patients with confirmed CDA diagnosis are encouraged to participate in the study.",{"count":327,"type":19},10000,"The investigators have created and maintain a comprehensive registry for patients with the diagnosis of Congenital Dyserythropoietic Anemia (CDA) in North America. The goal of this registry is to collect long-term confidential data on patients with CDA in the US, Canada, and Mexico and maintain a bio-repository of de-identified patient blood and bone marrow specimens as a tool for the investigation of epidemiology, natural history, biology, and molecular pathogenetic mechanisms of CDA.",[330],"Congenital Dyserythropoietic Anemia (CDA)",{"date":261,"type":33},{"date":333,"type":33},"2016-08-29",{"date":335,"type":19},"2031-01",{"name":39,"class":40},{"id":338,"slug":4,"hasResults":11,"nctId":339,"briefTitle":340,"officialTitle":340,"acronym":4,"eligibilityCriteria":341,"healthyVolunteers":11,"sex":16,"minAge":342,"maxAge":147,"enrollmentInfo":343,"targetDuration":4,"studyType":52,"phases":345,"briefSummary":346,"conditions":347,"keywords":356,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":367,"lastUpdatePostDateStruct":368,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":374},"100417438","NCT04715685","Mind Body Balance for Pediatric Migraine","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura or chronic migraine that meets the International Classification of Headache Disorders(ICHD) criteria\n* Frequency: Headache frequency based upon prospective headache diary of 28 days must be ≥ 4 and ≤ 28.\n* PedMIDAS: PedMIDAS Disability Score \\> 4, indicating at least mild disruption in daily activities and \\\u003C 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Use of one or more of the following prescribed nutraceuticals and\u002For preventive anti-migraine medications at the time or randomization or be on a stable dose of one or more of the following throughout the 12 weeks of the study \\[Vitamin B2 (Riboflavin), Co-Q 10 (Coenzyme Q10), Magnesium (Mg), Vitamin D2 or D3 (Erocalciferol\u002FCholecalciferol), Depakote (Divalproate), Inderal (Propanerol), Elavil ((Amitripyline), Topamax (Topiramate), Periactin (Cyproheptadine)\\]\n* Language: English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Continuous migraine defined as unrelenting headache for a 28 day period\n* Must agree not to take non-specific acute medication, such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications, such as triptans, more than 6 times per month (to prevent medication overuse headache)\n* PedMIDAS Disability Score \\> 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Youth who are pregnant, or those who are sexually active and not using a medically accepted form of contraception (barrier or hormonal methods)\n* Present severe psychiatric disease, alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) or other circumstances, that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study","10 Years",{"count":344,"type":19},260,[54],"This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.",[348,349,350,351,352,353,354,355],"Headache","Headache Disorders","Headache, Migraine","Migraine","Migraine Disorders","Migraine With Aura","Migraine Without Aura","Chronic Migraine",[357,358,359,360,361,362,363,364,365,366],"headache","migraine","cognitive behavioral therapy","pediatrics","mind body intervention","diaphragmatic breathing","progressive muscle relaxation","imagery","relaxation","biofeedback","2026-06-14",{"date":261,"type":33},{"date":370,"type":33},"2021-03-09",{"date":372,"type":19},"2026-11-30",{"name":39,"class":40},2,{"id":376,"slug":4,"hasResults":11,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":381,"targetDuration":4,"studyType":52,"phases":383,"briefSummary":385,"conditions":386,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":388,"lastUpdatePostDateStruct":389,"startDateStruct":391,"completionDateStruct":393,"leadSponsor":395,"locationsCount":41},"100477806","NCT05501756","Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation","Precision Alemtuzumab Dosing for Allogeneic Hematopoietic Cell Transplantation in Non-Malignant Diseases","Inclusion Criteria:\n\n* Patients who are undergoing allogeneic HCT at CCHMC with an alemtuzumab-containing preparative regimen for treatment of a non-malignant disease are eligible.\n* For the first 7 patients, patients must have a 10\u002F10 HLA matched related or unrelated stem cell donor, or be receiving a CD34+ selected stem cell product. After the first 7 patients, any donor match may be allowed after data review by the BMT clinicians and the PI.\n\nExclusion Criteria:\n\n* Patients with a history of anaphylaxis to alemtuzumab.\n* Patients who have previously received alemtuzumab and have not cleared alemtuzumab prior to the start of the preparative regimen.\n* Life expectancy less than 4 weeks.\n* Patients receiving dialysis or plasmapheresis at the time of the start of the conditioning regimen.\n* Failure to sign informed consent and\u002For assent, or inability to undergo informed consent process.\n* It is not medically advisable to obtain the specimens necessary for this study.\n* Not able to tolerate subcutaneous dosing (patients with severe skin conditions).\n* Patients with cancer.\n* Patients whose clinical condition suggest there may be inability to successfully perform the PK modeling such as, but not limited to, active flaring of hemophagocytic lymphohistiocytosis in which excessive lymphoproliferation may significantly alter the target-mediated clearance of alemtuzumab and prevent observation of non-target mediated clearance which is needed for robust modeling.\n* Patients whose pre-alemtuzumab level reveals an interfering substance which prevents accurate measurement of alemtuzumab.",{"count":382,"type":19},60,[384],"PHASE2","Alemtuzumab is an antibody that reduces the strength of the immune system that is given in preparation for allogeneic hematopoietic cell transplant (HCT). In this research study the investigators want to find out if they can adjust the dose of alemtuzumab used as part of allogeneic HCT to target the level of Day 0 (the planned day of graft infusion) to an optimal therapeutic window of 0.15-0.9 ug\u002FmL.",[387],"Allogeneic Hematopoietic Cell Transplantation","2026-06-10",{"date":390,"type":33},"2026-06-12",{"date":392,"type":33},"2023-01-11",{"date":394,"type":19},"2028-08-31",{"name":39,"class":40},{"id":397,"slug":4,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":399,"acronym":4,"eligibilityCriteria":400,"healthyVolunteers":11,"sex":16,"minAge":401,"maxAge":402,"enrollmentInfo":403,"targetDuration":4,"studyType":52,"phases":405,"briefSummary":406,"conditions":407,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":410,"startDateStruct":412,"completionDateStruct":414,"leadSponsor":416,"locationsCount":41},"100643832","NCT07635056","Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma","Inclusion Criteria:\n\n* Age 1-39 years at the time of study enrollment\n* With diagnosis of neuroblastoma with histologic verification\n* Classified as high-risk neuroblastoma as defined by Children's Oncology Group (COG) risk classification, including patients initially classified as low or intermediate risk at diagnosis with subsequent reclassification as high-risk disease\n* With relapsed or refractory disease, including at least one of the following:\n\n  1. Recurrent disease at any time after completion of frontline therapy\n  2. Progressive disease at any time following standard induction therapy\n  3. Primary resistant or refractory disease defined by failure to achieve a complete response by International Neuroblastoma Response Criteria (INRC) after at least four cycles of standard, multidrug induction chemotherapy on or according to a high-risk neuroblastoma protocol\n* Patients must have evaluable disease documented within four weeks of study enrollment. Evaluable disease must include at least one of the following:\n\n  1. Measurable tumor (\\>10 mm in at least one dimension) on MRI or CT scan that is either MIBG, FDG or 68Ga-DOTATATE avid\n  2. One or more MIBG, FDG, or 68Ga-DOTATATE avid bone lesion\n  3. Microscopic marrow metastasis based on routine morphology and\u002For immunohistochemistry in at least one sample from bilateral aspirates and biopsies at the time of study enrollment.\n* With performance level of \\>50% on Lansky (\\\u003C16 years) or Karnofsky (\\>16 years) scales. Patients who are wheelchair bound due to paralysis will be considered ambulatory when assessing their performance score.\n* Adequate baseline cardiac and pulmonary function including a left ventricular ejection fraction (LVEF) \\>50% by echocardiogram and pulse oximetry \\>92% on room air documented within four weeks of study enrollment.\n* Adequate baseline hematologic function: peripheral absolute neutrophil count (ANC) ≥500\u002FµL, with no receipt of long-acting myeloid growth factors within 14 days or short-acting myeloid growth factors within 7 days of study entry, and a platelet count ≥50,000\u002FµL, with patients required to be transfusion independent for at least 7 days, unless cytopenias are related to marrow metastasis as defined above.\n* With available haploidentical related donors.\n\nExclusion Criteria:\n\n* Infectious disease: Active, uncontrolled infection or received a live vaccine within 30 days prior to study enrollment.\n* Cardiac function: LVEF \\\u003C50% by echocardiogram, serious uncontrolled cardiac arrhythmias, or history of myocarditis or congestive heart failure (New York Heart Association Functional Classification III or IV)\n* Pulmonary function: Active interstitial lung disease (ILD)\u002Fpneumonitis or history of ILD\u002Fpneumonitis requiring systemic corticosteroid treatment.\n* Renal function: Glomerular Function Rate (GFR) \\\u003C50 mL\u002Fmin\u002F1.73 m2 as measured by cystatin C or NM GFR\n* Hepatic function: Total bilirubin \\>5 mg\u002FdL, AST and ALT \\>10 times the upper limit of normal\n* Concomitant medications: receiving \\>0.5 mg\u002Fkg prednisone equivalent daily\n* Receipt of any concomitant investigational treatments within 30 days at the time of the infusion of the IP. These investigational treatments include drugs, biologics, or devices that are still under investigation in clinical trials or research settings. The use of such agents may confound study results or pose additional safety risks\n* Known allergy or hypersensitivity reaction to IL-2 injections\n* Pregnant or breastfeeding women","1 Year","39 Years",{"count":404,"type":19},20,[384],"The goal of this study is to demonstrate that cytokine-induced memory-like natural killer cells (CIML-NK cells) can be generated from donor cells and infused safely into patients with relapsed or refractory neuroblastoma during dinutuximab-based therapy.",[408],"Neuroblastoma","2026-06-04",{"date":411,"type":33},"2026-06-09",{"date":413,"type":19},"2026-07",{"date":415,"type":19},"2031-06",{"name":39,"class":40},{"id":418,"slug":4,"hasResults":11,"nctId":419,"briefTitle":420,"officialTitle":420,"acronym":421,"eligibilityCriteria":422,"healthyVolunteers":49,"sex":16,"minAge":342,"maxAge":147,"enrollmentInfo":423,"targetDuration":4,"studyType":52,"phases":425,"briefSummary":426,"conditions":427,"keywords":433,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":409,"lastUpdatePostDateStruct":435,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":441,"locationsCount":41},"100501841","NCT05814497","Supraspinal Processing of Sensory Aspects of Pain","SCP","Inclusion Criteria:\n\n* Patients will need a diagnosis of a chronic pain derived congruent with ICD-11 criteria related to headache (migraine, daily headache), abdominal (FAPD), localized MSK (single limb\u002Fjoint, low back or chest pain), diffuse MSK (widespread MSK pain), or CRPS\n* If on medications, they need to be on stable doses of prescribed pain and\u002For psychiatric medications for 4 weeks before the baseline study visit.\n* Male or female, age 10 -17 (inclusive)\n* English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Weight\u002Fsize incompatible with MRI scanner\n* Orthodontic braces, metallic or electronic implants, or other metal objects in the body which obscure or interfere with the MRI, or pose a risk from heating, movement, or malfunction in the MRI environment\n* Claustrophobia\n* Youth who are pregnant\n* Any comorbid rheumatic disease, diagnosis of epilepsy, other neurological diseases, or medical condition (e.g. diabetes, cancer, IBD)\n* Present psychiatric disease as defined by DSM IV (e.g. psychosis, bipolar disorder, major depression, generalized anxiety disorder), alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, ADHD, or mental retardation) that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study\n* Skin conditions or past skin damage on the arms or legs in or near sites of sensory testing\n* Outside the age range (9 years old or younger; 18 years or older) at the time of consent\n* History of \\> 1 month opioid treatment.",{"count":424,"type":19},255,[54],"The goal of this basic science study is to learn about the brain mechanisms of chronic pain across different chronic pain syndromes in pediatric patients. The main questions it aims to answer are:\n\n* Are there shared and distinct brain systems engaged by different forms of pediatric chronic pain?\n* What are predictors of recovery from chronic pain?\n* What brain systems are associated with the spread of pain?\n\nFor this study participants will undergo:\n\n* Functional Magnetic Resonance Imaging (fMRI)\n* Quantitative Sensory Testing\n* Psychological Assessments",[428,429,430,431,432],"Migraine in Children","Complex Regional Pain Syndromes","Musculoskeletal Pain","Functional Abdominal Pain Syndrome","Fibromyalgia",[434],"chronic pain",{"date":436,"type":33},"2026-06-05",{"date":438,"type":33},"2023-05-01",{"date":440,"type":19},"2027-06-30",{"name":39,"class":40},{"id":443,"slug":4,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":49,"sex":16,"minAge":449,"maxAge":72,"enrollmentInfo":450,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":457,"lastUpdatePostDateStruct":458,"startDateStruct":459,"completionDateStruct":460,"leadSponsor":462,"locationsCount":41},"100643155","NCT07636525","Sleep and Adolescent Vaccine Immunogenicity Pilot\u002FObservational Study","Sleep and Adolescent Vaccine Immunogenicity (SAVI) Pilot Study","SAVI","Inclusion Criteria:\n\n* Healthy 11-12 years olds who have neither had initial meningococcal vaccination nor known exposure to meningococcal illness.\n\nExclusion Criteria:\n\n* Condition or treatment resulting in immunosuppression\n* Prior severe vaccine reaction\n* Symptoms of clinical insomnia or organic sleep disorder\n* Known neurologic condition or intellectual\u002Fdevelopmental disability\n* Use of a medication that impacts sleep\n* Average nightly sleep of 8-8.99 hours (between the two groups)\n* Daily intake of \\>1 coffee or \"energy drink\" or \\>2 caffeinated sodas.","11 Years",{"count":451,"type":19},66,"The main reason for this research study is to understand whether the sleep habits of 11-12 years-olds impact their response to a vaccine. The vaccine is called MCV4. It protects against meningococcal illness, which is rare but can be severe. The American Academy of Pediatrics recommends that the vaccine be given at age 11 or 12. The vaccine has been approved for youth in this age range for over 20 years and is one of the vaccines that primary care doctors typically give around this age. However, nobody has studied how sleep affects children's response to it. This could be important because research on adults suggests that sleep affects the immune system. We want to look at that issue in a younger age range.\n\nParticipating families will be asked to have their child keep their regular sleep schedule during the 5-week study, without much variation. During that time, they will wear a special wristwatch at night to track their sleep. Each day they will fill out a short online form. They and a parent\u002Fguardian will come to Cincinnati Children's twice. Each visit will last 1 - 1 ½ hours. The first visit will happen at the end of the 1st week. The second is at the end of the 5th week. During visits, they will fill out forms and we will get data from the wristwatch. During the first visit, the participating child would get the vaccine. During the second, they will have a blood test.",[454],"Vaccination",[456],"Sleep","2026-06-03",{"date":411,"type":33},{"date":413,"type":19},{"date":461,"type":19},"2027-07",{"name":39,"class":40},{"id":464,"slug":4,"hasResults":11,"nctId":465,"briefTitle":466,"officialTitle":467,"acronym":4,"eligibilityCriteria":468,"healthyVolunteers":11,"sex":16,"minAge":469,"maxAge":470,"enrollmentInfo":471,"targetDuration":4,"studyType":20,"phases":4,"briefSummary":473,"conditions":474,"keywords":493,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":503,"locationsCount":504},"100526212","NCT06131801","Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution","A Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution in Children and Young Adults With Hematologic Malignancies","Inclusion Criteria:\n\n* Age: Patients must be \\\u003C39 years of age at time of study enrollment\n* Diagnosis: Patients may have a diagnosis of any hematologic malignancy\n* Central access: Patients must have an existing venous or arterial access line for PK blood draws\n* Weight requirement: Patients must weigh at least 5.5 kg at the time of enrollment\n* Venetoclax: Patients must be receiving any dose of venetoclax given as a solution made from crushed tablets by mouth (PO) or via nasogastric (NG), or G-tube as prescribed by their treating oncologist.\n* Concurrent chemotherapy medications: Patients may receive venetoclax as a single agent or in combination with any other chemotherapeutic agents.\n\nExclusion Criteria:\n\n* Pregnant women are excluded from this study because venetoclax has the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with venetoclax, breastfeeding should be discontinued if the mother is treated with venetoclax.\n* Males or females of reproductive potential may not participate unless they have agreed to use an effective contraceptive method while on study treatment and for six months following completion.","0 Years","38 Years",{"count":472,"type":19},30,"The use of venetoclax-based therapies for pediatric patients with relapsed or refractory malignancies is increasingly common outside of the clinical trial setting. For patients who cannot swallow tablets, it is common to crush the tablets and dissolve them in liquid to create a solution. However, no PK data exists in adults or children using crushed tablets dissolved in liquid in this manner, and as a result, the venetoclax exposure with this solution is unknown.\n\nPrimary Objectives\n\n• To determine the pharmacokinetics of venetoclax when commercially available tablets are crushed and dissolved into a solution\n\nSecondary Objectives\n\n* To evaluate the safety of crushed venetoclax tablets administered as an oral solution\n* To determine the pharmacokinetics of venetoclax solution in patients receiving concomitant strong and moderate CYP3A inhibitors\n* To determine potential pharmacokinetic differences based on route of venetoclax solution administration (ie. PO vs NG tube vs G-tube)\n* To determine the concentration of venetoclax in cerebral spinal fluid when administered as an oral solution",[475,476,477,478,16,479,480,481,482,483,484,485,486,487,488,489,490,491,492],"Hematologic Malignancy","Leukemia","Lymphoma","Acute Lymphocytic Leukemia","Acute Myelogenous Leukemia","AML","Chronic Myelogenous Leukemia","CML","Myeloproliferative Neoplasm","Non Hodgkin Lymphoma","Hodgkin Lymphoma","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Burkitt Lymphoma","T-cell Lymphoma","B Cell Lymphoma","Peripheral T Cell Lymphoma","Cutaneous B-Cell Lymphoma",[494,495,496],"Venetoclax","Pediatric AML","Pediatric Relapsed\u002FRefractory AML","2026-06-02",{"date":409,"type":33},{"date":500,"type":33},"2023-11-15",{"date":502,"type":19},"2027-12-01",{"name":39,"class":40},5,{"id":506,"slug":4,"hasResults":11,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":11,"sex":16,"minAge":96,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":52,"phases":513,"briefSummary":515,"conditions":516,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":519,"startDateStruct":520,"completionDateStruct":522,"leadSponsor":524,"locationsCount":41},"100640754","NCT07628972","Quercetin Dyskeratosis Congenita (DC)\u002FTelomere Biology Disorders (TBD)","Pilot Study of Quercetin Patients With Dyskeratosis Congenita\u002FTelomere Biology Disorders","Inclusion Criteria:\n\n1. Diagnosis of DC\u002FTBD deficiency as defined by at least one of the following:\n\n   * Age adjusted mean-telomere length of \\\u003C1 percentile in all tested peripheral blood cells such as granulocytes, lymphocytes, B-cells, naïve T-cells, memory T-cells, and NK cells\n   * A pathogenic or likely pathogenic mutation in DKC1, TERC, TERT, NOP10, NHP2, TINF2, CTC1, PARN, RTEL1, ACD, NAF1, ZCCHC8, or WRAP53\n2. Patients ≥ 2.0 years of age\\*\n\n   * The first three enrolled patients must be ≥ 10.0 years of age\n3. Able to take medication orally\n\nExclusion Criteria:\n\n1. Renal failure requiring dialysis\n2. Total bilirubin \\>3 mg\u002Fdl and\u002For SGPT \\>300 at time of enrollment, unless elevation thought to be related to DC\u002FTBD\n3. Patients who have received quercetin or any over-the-counter antioxidant supplementation within last 1 month\n4. Patients currently taking androgen therapy\n5. Patients receiving digoxin therapy, who are unable to discontinue treatment due to medical reasons\n6. Patients receiving fluoroquinolone therapy, who are unable to discontinue treatment due to medical reasons\n7. Patients who are pregnant or breastfeeding or are at risk of pregnancy and are unable to use acceptable methods of birth control during the length of the study\n8. Patients with morphologic or cytogenetic evidence of myelodysplasia or leukemia.\n9. Patients needing to start or actively receiving radiation therapy, chemotherapy or immunotherapy for treatment of SCC or other cancers.\n10. Patients with unstable disease status or other medical issues requiring hospitalization or rapid escalation of medical care\n11. Participating in another therapeutic study for DC\u002FTBD\n12. Patients who are in the early post-stem cell transplant period (i.e. first 6 months post-transplant)",{"count":512,"type":19},12,[514],"PHASE1","The purpose of this study is to see if a vitamin-like substance called quercetin is safe for people who have a rare condition called Dyskeratosis congenita (DC) or telomere biology disorders (TBD).",[517,518],"Dyskeratosis Congenita","Telomere Disease",{"date":436,"type":33},{"date":521,"type":33},"2026-05-29",{"date":523,"type":19},"2028-09",{"name":39,"class":40},{"id":526,"slug":4,"hasResults":11,"nctId":527,"briefTitle":528,"officialTitle":528,"acronym":529,"eligibilityCriteria":530,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":52,"phases":533,"briefSummary":534,"conditions":535,"keywords":536,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":543,"completionDateStruct":545,"leadSponsor":547,"locationsCount":41},"100640746","NCT07599956","Artificial Intelligence to Scale Early Rheumatic Heart Disease Detection","SHIELD 1","Inclusion Criteria:\n\n* Employed at a participating ADUNU facility\n* Holds a designated role in the ADUNU program as a nurse screener\n\nExclusion Criteria:\n\n* None. The pragmatic trial design includes all eligible staff at participating facilities.",{"count":532,"type":19},62,[54],"The main goal of this project is to see if RADAR (Rapid AI-assisted Detection and Analysis of Rheumatic heart disease), which is a machine and deep-learning AI model, can help make rheumatic heart disease (RHD) screening easier to expand. Specifically, the project will test whether RADAR can screen as accurately-or more accurately-than current methods, and whether it can be used effectively in different low-resource settings. The aim is to show that RADAR could be adopted and used widely around the world.",[57],[59,537,538,539],"Artificial Intelligence","Deep Learning","Machine Learning","2026-05-22",{"date":542,"type":33},"2026-05-27",{"date":544,"type":19},"2026-06",{"date":546,"type":19},"2028-06",{"name":39,"class":40},{"id":549,"slug":4,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":47,"eligibilityCriteria":48,"healthyVolunteers":49,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":550,"targetDuration":4,"studyType":52,"phases":551,"briefSummary":55,"conditions":552,"keywords":553,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":554,"lastUpdatePostDateStruct":555,"startDateStruct":557,"completionDateStruct":558,"leadSponsor":559,"locationsCount":41},"100638280",{"count":51,"type":19},[54],[57],[59,60],"2026-05-19",{"date":556,"type":33},"2026-05-26",{"date":199,"type":19},{"date":64,"type":19},{"name":39,"class":40},{"id":561,"slug":4,"hasResults":11,"nctId":562,"briefTitle":563,"officialTitle":564,"acronym":565,"eligibilityCriteria":566,"healthyVolunteers":11,"sex":16,"minAge":567,"maxAge":568,"enrollmentInfo":569,"targetDuration":571,"studyType":20,"phases":4,"briefSummary":572,"conditions":573,"keywords":4,"overallStatus":81,"whyStopped":4,"lastUpdateSubmitDate":579,"lastUpdatePostDateStruct":580,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":41},"100640924","NCT07602595","The BRIDGE Pain Study","Biopsychosocial Risk Influences on the Development and Generation of Early-Onset Chronic Pain","BRIDGE","Inclusion Criteria:\n\n* Diagnosis of rheumatic\u002Fautoimmune disease\u002Fpain condition or surgery prior to age 18; Current age 14 to 26 years; Participant (and parent\u002Flegal guardian of participants \\\u003C 18 yo) can read and write in English; At least 1 year from diagnosis of pain or rheumatic disease; For individuals with MSK surgical history, at least 1 year after initial surgical intervention; For individuals with rheumatic disease, their disease must be considered inactive\n\nExclusion Criteria:\n\n* They have active disease, or Other major medical comorbidities have developed after surgery following MSK surgical intervention.","14 Years","26 Years",{"count":570,"type":19},600,"4 Weeks","The purpose of the study is to discover at least two distinct Musculoskeletal pain subtypes. These types are caused by different brain-and-immune system signals that affect how the body feels pain, and they are also shaped by a person's biology, psychology, and social environment.\n\nAim 1. We want to sort adolescents and young adults with long lasting muscle and bone pain into two different groups. To do this, we will look at participants' childhood medical histories, past treatments, when their pain started, the sex they were assigned at birth, what their pain feels like now, tests of how their body senses pain, and immune system markers found in their blood. We think we will find at least two different types of chronic pain groups, plus one group of patients who had a higher risk for pain (because of a rheumatic disease or past surgery) but never developed long term pain.\n\nAim 2. We want to find out if certain patterns of inflammation in the body change how nerve cells react to pain.\n\nAim 3: We want to understand how different biological, psychological, and social factors are connected to the chronic pain groups we identified. We think we will find certain mental, behavioral, and social risks-as well as protective factors-that help explain why some people develop long-lasting pain and others do not. We expect these factors to play different roles in each pain group, including the group that does not develop chronic pain.",[574,432,575,576,577,578,430],"Juvenile Idiopathic Arthritis (JIA)","Lupus","Scoliosis","Pectus Excavatum","Chronic Pain","2026-05-16",{"date":540,"type":33},{"date":582,"type":19},"2026-08",{"date":584,"type":19},"2029-08",{"name":39,"class":40},""]